Bayer Reports Apollo Capital Injection Strengthens Debt-Reduction Outlook
Bayer’s balance sheet improves as a €3.0 billion capital injection linked to the Apollo transaction approaches a planned Q3 2026 close. Q2 2026 revenue rose to €10.9 billion and EBITDA to €2.1 billion, though core EPS fell to €0.95. Target price revisions follow, including UBS raising its view to €62, amid a continuing glyphosate legal overhang and a final non-binding federal court statement.